BDNF, TNFα, HSP90, CFH, and IL-10 Serum Levels in Patients with Early or Late Onset Alzheimer's Disease or Mild Cognitive Impairment
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Identifying early-detection biomarkers have become an increasingly important approach in the treatment and prevention of Alzheimer's disease (AD). In this study, we investigated the potential of brain-derived neurotrophic factor (BDNF), complement factor H (CFH), tumor necrosis factor-α (TNFα), interleukin 10 (IL-10), and heat shock protein 90 (Hsp90) as serum biomarkers for AD in a cohort of the Turkish population because they have been suggested to be associated with AD. Serum BDNF, CFH, TNFα, IL-10, and Hsp90 levels in three groups of patients, early-onset AD (EOAD; age of onset 65; n = 54), and mild cognitive impairment (MCI) (n = 30), were compared with age-matched healthy controls (age 65; n = 32) using ELISA. The serum BDNF levels significantly decreased and TNFα levels significantly increased in the EOAD and LOAD groups compared to the age-matched healthy controls. There was a correlation between serum TNFα and IL-10 levels in the LOAD and healthy control groups. Serum CFH levels in the LOAD and MCI patients were significantly decreased compared with controls. Serum Hsp90 levels in the EOAD, LOAD, and MCI patients were significantly decreased compared with controls. The protein misfolding, the inflammatory response, and decreased neurotrophic factor synthesis are all suggested to be related to AD type brain pathology, and our results indicate these alterations might be traced from serum samples. For accurate early diagnosis of AD, it is important to determine a profil…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as in AD patients’ CSF and serum [215,216,217,218,219,220,221,222]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [221]
In the citing paper
“In humans, two studies have shown an increase in pro-inflammatory cytokines and a decrease in BDNF levels in the serum of early- and late-onset AD, although there was no correlation with pro-inflammatory and neurotrophin results in both studies [141, 156].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
In the citing paper
“BDNF levels are also reduced in plasma of patients with mild cognitive impairment (MCI) [140] and AD [141].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [141]
Citations
Cites
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 1×
“…plasticity, neuronal neuronal survival, and differentiation, where it participates BDNF mRNA and protein levels in the hippocampus and neocortex of AD patients suggest that BDNF of BDNF have been reported in the hippocampus [9 and BDNF can mediate rapid dephosphorylation of tau protein [4].”
Brain-derived neurotrophic factor is reduced in Alzheimer's disease
Connor, B., Young, D., Yan, Q., Faull, R. L. M., Synek, B., & Dragunow, M. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00125-3 · Cited by 581
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571
Proteome-based plasma biomarkers for Alzheimer's disease
Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., et al. (2006) · Brain · doi:10.1093/brain/awl279 · Cited by 464
Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro
Evans, C. G., Wisén, S., & Gestwicki, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606192200 · Cited by 382 · cited 1×
“Studies suggest that chaperones may have role in AD [30, 31].”
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335
Holsinger, R. M. D., Schnarr, J., Henry, P., Castelo, V. T., & Fahnestock, M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00023-1 · Cited by 328
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.014 · Cited by 272
Magrané, J., Smith, R. C., Walsh, K., & Querfurth, H. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4330-03.2004 · Cited by 242
Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients
Laske, C., Stellos, K., Hoffmann, N., Stransky, E., Straten, G., Eschweiler, G. W., & Leyhe, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001008 · Cited by 180
Cited by
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., Ortolano, S., Pani, G., Athanasopoulou, S., Gonos, E. S., et al. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.004 · Cited by 475
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Ng, T. K. S., Ho, C. S. H., Tam, W. W. S., Kua, E. H., & Ho, R. C.-M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020257 · Cited by 413
“…elders recruited from an ongoing cohort study Mayo Clinic criteria 0.51 (0.27) 62; M = 17, F= 45 72.2 (6.2) 88; M = 25, F = 63 Gezen-ak et al. (2013) [29] Istanbul, Turkey Behavioral Neurology and Movement Disorder Clinic DSM-VI and MMSE 0.93 (0.31) 76; NA; EOAD = 22, LOAD…”
BackgroundInfluentialThe involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease
Josiane, Tatiani, Francielle, Michelle, & Alexandra (2015) · Aging and disease · doi:10.14336/ad.2015.0825 · Cited by 407
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Neuroinflammation in Alzheimer’s disease
Zhang, F., & Jiang, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75546 · Cited by 276
Azman, K. F., & Zakaria, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126827 · Cited by 221
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy
Song, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8958-4 · Cited by 237
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237
Self-citationKim, H., Suzuki, T., Kim, M., Kojima, N., Ota, N., Shimotoyodome, A., Hase, T., Hosoi, E., & Yoshida, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116256 · Cited by 210
Inflammatory biomarkers in Alzheimer's disease plasma
Morgan, A. R., Touchard, S., Leckey, C., O'Hagan, C., Nevado‐Holgado, A. J., NIMA Consortium, Barkhof, F., Bertram, L., Blin, O., Bos, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.007 · Cited by 207
Nascimento, C., Pereira, J., Andrade, L., Garuffi, M., Talib, L., Forlenza, O., Cancela, J., Cominetti, M., & Stella, F. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910122849 · Cited by 192
Chen, H., Liu, S., Ji, L., Wu, T., Ji, Y., Zhou, Y., Zheng, M., Zhang, M., Xu, W., & Huang, G. (2016) · Mediators of Inflammation · doi:10.1155/2016/5912146 · Cited by 202
Shimada, H., Makizako, H., Doi, T., Yoshida, D., Tsutsumimoto, K., Anan, Y., Uemura, K., Lee, S., Park, H., & Suzuki, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00069 · Cited by 188
Interleukin-10: A Pleiotropic Regulator in Pregnancy
Cheng, S.-B., & Sharma, S. (2015) · American Journal of Reproductive Immunology · doi:10.1111/aji.12329 · Cited by 184
Yang, W., Liu, Y., Xu, Q.-Q., Xian, Y.-F., & Lin, Z.-X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4754195 · Cited by 176
Astrocyte Senescence and Alzheimer’s Disease: A Review
Han, X., Zhang, T., Liu, H., Mi, Y., & Gou, X. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00148 · Cited by 177
“Several SASP factors, including IL-6, IL-1β, TNF-α, MMP-1, MMP-3, and MMP-10, have also been found to be elevated in the cerebrospinal fluid (CSF) and serum of AD patients (Wood et al., 1993; BlumDegena et al., 1995; Leake et al., 2000; Horstmann et al., 2010; Gezen-Ak et al., 2013).”
BackgroundHeat shock proteins in neurodegenerative disorders and aging
Leak, R. K. (2014) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-014-0243-9 · Cited by 166
“…al. 2006 Temporal cortex − Alzheimer's disease Male and female humans combined Yokota et al. 2006 Blood − Alzheimer's disease Gender not specified in humans Gezen-Ak et al. 2013 Hippocampus + Aging Male Mongolian gerbils Lee et al. 2011 Blood + Aging No gender difference in humans Njemini et al.…”
Tsai, C.-L., Pai, M.-C., Ukropec, J., & Ukropcová, B. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190228125429 · Cited by 156
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 153
Zhang, M., Cheng, Q., Zheng, Z., Qian, F., Wang, Y., Thu, P. M., Zhang, X., Zhou, Y., Tu, L., Liu, Q., et al. (2018) · Theranostics · doi:10.7150/thno.26164 · Cited by 160
“The function and content of HSP90 were found to be greatly impaired in old animals [21], as well as in patients with early or late onset AD or mild cognitive impairment [22].”
BackgroundEyileten, C., Sharif, L., Wicik, Z., Jakubik, D., Jarosz-Popek, J., Soplińska, A., Postula, M. A., Członkowska, A., Kapłon‐Cieślicka, A., & Mirowska-Guzel, D. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02101-2 · Cited by 158
Qin, X.-Y., Cao, C., Cawley, N. X., Liu, T.-T., Yuan, J., Loh, Y. P., & Cheng, Y. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.62 · Cited by 142
Unfolding the Role of BDNF as a Biomarker for Treatment of Depression
Rana, T., Behl, T., Sehgal, A., Srivastava, P., & BUNGAU, S. G. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01754-x · Cited by 146
“The plasma levels of BDNF are also decreased in patients with Alzheimer’s disease (Gezen-Ak et al. 2013).”
BackgroundThe Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration
Pisani, A., Paciello, F., VECCHIO, V. D., Malesci, R., Corso, E. D., Cantone, E., & Fetoni, A. R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040652 · Cited by 138
Eyileten, C., Kapłon‐Cieślicka, A., Mirowska-Guzel, D. M., Małek, Ł. A., & Postula, M. A. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2823671 · Cited by 135
Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: Recent developments
Zhao, H., Alam, A., San, C.-Y., Eguchi, S., Chen, Q., Lian, Q., & Ma, D. (2017) · Brain Research · doi:10.1016/j.brainres.2017.03.029 · Cited by 122
Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
Baird, A. L., Westwood, S., & Lovestone, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00236 · Cited by 119
New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer’s Disease
Guzmán‐Martínez, L., Calfío, C., Farias, G. A., Vilches, C., Prieto, R., & Maccioni, R. B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201059 · Cited by 120
“, are associated with increased cognitive loss in AD patients [23].”
Comorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness
Duric, V., Clayton, S., Leong, M. L., & Yuan, L.-L. (2016) · Neural Plasticity · doi:10.1155/2016/5460732 · Cited by 98
Ma, F., Wu, T., Zhao, J., Song, A., Liu, H., Xu, W., & Huang, G. (2016) · Scientific Reports · doi:10.1038/srep37486 · Cited by 105
Protective effects of resveratrol on aging-induced cognitive impairment in rats
Göçmez, S. S., Gacar, N., Utkan, T., Gacar, G., Scarpace, P. J., & Tümer, N. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.03.022 · Cited by 109
“Furthermore, in previous studies, reduced serum levels of BDNF have been documented in Alzheimer’s Disease, mild cognitive impairment and major depressive disorder (Gezen-Ak et al., 2013; Karege et al., 2002; Peng, Wuu, Mufson, & Fahnestock, 2005).”
Garcez, M. L., Mina, F., Bellettini-Santos, T., Carneiro, F. G., Luz, A. P., Schiavo, G. L., Andrighetti, M. S., Scheid, M. G., Bolfe, R. P., & Budni, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.010 · Cited by 102
Why Vitamin D in Alzheimer's Disease? The Hypothesis
Gezen‐Ak, D., Yılmazer, S., & Dursun, E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131970 · Cited by 109
Self-citationHeat Shock Protein 90 in Alzheimer’s Disease
Ou, J.-R., Tan, M., Xie, A., Yu, J., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/796869 · Cited by 116
Innate Immunity Fights Alzheimer's Disease
Guillot-Sestier, M.-V., Doty, K. R., & Town, T. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.008 · Cited by 102
“Increased IL-10 abundance in AD patients’ sera and brains has been reported [25,48], and we recently showed that all canonical IL-10 pathway signaling elements (i.”
BackgroundSerum miR-206 and miR-132 as Potential Circulating Biomarkers for Mild Cognitive Impairment
Xie, B., Zhou, H., Zhang, R., Song, M., Yu, L., Wang, L., Liu, Z., Zhang, Q., Cui, D., Wang, X., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142847 · Cited by 97
Shi, L., Baird, A. L., Westwood, S., Hye, A., Dobson, R., Thambisetty, M., & Lovestone, S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170531 · Cited by 90
Cespón, J., Miniussi, C., & Pellicciari, M. C. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.03.001 · Cited by 106
Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease
Girotra, P., Behl, T., Sehgal, A., Singh, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01824-8 · Cited by 92
An overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 98
Biomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87
Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy
Mazzaro, N., Barini, E., Spillantini, M. G., Goedert, M., Medini, P., & Gasparini, L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-15.2016 · Cited by 94
“Among the neurotrophins, brain-derived neurotrophic factor (BDNF) plays a key role in promoting neuronal survival, synaptic plasticity, and memory consolidation (Lu, 2003; Binder and Scharfman, 2004; Gezen-Ak et al., 2013).”
Balietti, M., Giuli, C., & Conti, F. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0866-y · Cited by 91
Kaźmierski, J., Banyś, A., Latek, J., Bourke, J. H., Jaszewski, R., Sobów, T., & Kłoszewska, I. (2014) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000357454 · Cited by 89
Alcohol-Mediated Organ Damages: Heart and Brain
Obad, A. S., Peeran, A. A., Little, J. I., Haddad, G. E., & Tarzami, S. T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00081 · Cited by 88
Mori, Y., Tsuji, M., Oguchi, T., Kasuga, K., Kimura, A., Futamura, A., Sugimoto, A., Kasai, H., Kuroda, T., Yano, S., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.653267 · Cited by 79
“Although the association between cognitive decline and reduction in blood BDNF levels has been reported, it has also been shown to decrease in AD (12, 13) and MCI (14, 15).”
BackgroundKarim, Y., Siddique, A. E., Hossen, F., Rahman, M., Mondal, V., Banna, H. U., Hasibuzzaman, M. M., Hosen, Z., Islam, M. S., Sarker, M. K., et al. (2019) · Environment International · doi:10.1016/j.envint.2019.105029 · Cited by 83
Raised Serum Proinflammatory Cytokines in Alzheimer’s Disease with Depression
Khemk, V. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500170 · Cited by 74
“Apart from the detailed studies of the inflammatory changes in AD brain, there also exists a surfeit of studies showing altered levels of proinflammatory cytokines in peripheral circulation in AD subjects [4-7,20,21].”
BackgroundResultYin, P., Wang, X., Wang, S., Wei, Y., Feng, J., & Zhu, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00466 · Cited by 73
CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer’s Disease
Initiative, A. D. N., Zhang, D., Li, J., Wu, H., Cui, Y. J., Bi, R., Zhou, H., Wang, H.-Z., Zhang, C., Wang, D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.232 · Cited by 78
“…there are some controversies regarding serum CFH level in AD: an increase of CFH level was observed in the serum of AD patients (Hye et al, 2006, 2014); however, serum CFH level was reported to be significantly downregulated in patients with AD and mild cognitive impairment (Gezen-Ak et al, 2013).”
BackgroundMicroRNA expression data analysis to identify key miRNAs associated with Alzheimer's disease
Chen, J., Yan, Q., Liu, C., Lu, J., Shi, J., & Shi, Y. X. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3014 · Cited by 70
“In addition, we investigated the functions of dysregulated miRNA target genes in the pathological process of AD.”
ResultInfluentialSerum pro-BDNF levels correlate with phospho-tau staining in Alzheimer's disease
Bharani, K., Ledreux, A., Gilmore, A., Carroll, S. L., & Granholm, A. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.010 · Cited by 66
Serum IL‐8 is a marker of white‐matter hyperintensities in patients with Alzheimer's disease
Zhu, Y., Chai, Y. L., Hilal, S., Ikram, M. K., Venketasubramanian, N., Wong, B., Chen, C. P., & Lai, M. K. P. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.001 · Cited by 62
Brosseron, F., Maaß, A., Kleineidam, L., Ravichandran, K. A., Kolbe, C., Wolfsgruber, S., Santarelli, F., Häsler, L. M., McManus, R. M., Ising, C., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01118-0 · Cited by 63
Angelucci, F., Čechová, K., Průša, R., & Hort, J. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13082 · Cited by 64
The Role of Glial Cell Senescence in Alzheimer's Disease
Alshaebi, F., Sciortino, A., & Kayed, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70051 · Cited by 60
Sharma, V., Singh, T. G., Kaur, A., Mannan, A., & Dhiman, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03755-1 · Cited by 59
Gut microbiota in dementia with Lewy bodies
Nishiwaki, H., Ueyama, J., Kashihara, K., Ito, M., Hamaguchi, T., Maeda, T., Tsuboi, Y., Katsuno, M., Hirayama, M., & Ohno, K. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00428-2 · Cited by 70
Keifer, J. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25022 · Cited by 61
Unlocking Alzheimer’s Disease: The Role of BDNF Signaling in Neuropathology and Treatment
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Hemeda, L. R., Faheem, S. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08857-x · Cited by 59
“However, Gezen-Ak et al. (Gezen-Ak et al., 2013) highlighted that the level of BDNF is dropped in AD individuals with both early and late onset due to a progressive accumulation of Aβ within brain neurons, and associated neurodegeneration could be the possible mechanism for the reduction of BDNF levels.”
Li, M., Li, W., Gao, Y., Chen, Y., Bai, D. G., Weng, J., Du, Y. J., Ma, F., Wang, X., Liu, H., et al. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02373-3 · Cited by 59
Peineau, S., Rabiant, K., Pierrefiche, O., & Potier, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.018 · Cited by 60
Kim, B. Y., Lee, S. H., Graham, P. L., Angelucci, F., Lucía, A., Pareja-Galeano, H., Leyhe, T., Turana, Y., Lee, I. R., Yoon, J. H., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0192-9 · Cited by 59
“Among the abovementioned 5 articles that were excluded, 4 did not report standard deviation [54, 55, 57, 58].”
BackgroundParamasivam, P., Poongothai, S., Shanthirani, C. S., Anjana, R. M., Mohan, V., & Balasubramanyam, M. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01486-9 · Cited by 56
Tang, X., Chang, C., Hao, M., Chen, M., Woodley, D. T., Schönthal, A. H., & Li, W. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00316-6 · Cited by 52
Seeking an Objective Diagnosis of Depression
Bilello, J. A. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0076 · Cited by 48
Chaperones—A New Class of Potential Therapeutic Targets in Alzheimer’s Disease
Batko, J., Antosz, K., Miśków, W., Pszczołowska, M., Walczak, K., & Leszek, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063401 · Cited by 51
Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease
Ouma, S., Suenaga, M., Hatip, F. F. B., Hatip‐Al‐Khatib, I., Tsuboi, Y., & Matsunaga, Y. (2018) · Brain and Behavior · doi:10.1002/brb3.936 · Cited by 51
Ruthirakuhan, M., Herrmann, N., Andreazza, A. C., Verhoeff, N. P. L. G., Gallagher, D., Black, S. E., Kiss, A., & Lanctôt, K. L. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988719874118 · Cited by 46
Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARα
Patel, D. R., Roy, A., Raha, S., Kundu, M., Gonzalez, F. J., & Pahan, K. (2020) · JCI Insight · doi:10.1172/jci.insight.136654 · Cited by 60
“Interaction statistics between 2 independent variables was calculated [F(2,12) = 9.”
BackgroundMethodInfluentialBlood biomarkers in Alzheimer’s disease
Altuna, M., & Mendióroz, M. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2018.03.006 · Cited by 55
Spiers, J. G., Chen, H.-J. C., Bourgognon, J.-M., & Steinert, J. R. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.01.025 · Cited by 45
Do serum GDNF levels correlate with severity of Alzheimer’s disease?
Sharif, M. O., Noroozıan, M., & Hashemian, F. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04909-1 · Cited by 50
Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment
Scassellati, C., Ciani, M., Galoforo, A. C., Zanardini, R., Bonvicini, C., & Geroldi, C. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111210 · Cited by 48
Biomarkers for Alzheimer's disease
Pauwels, E. K. J., Volterani, D., & Marlani, G. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.3.1354128 · Cited by 42
Ghosh, P., Singh, R., Ganeshpurkar, A., Pokle, A. V., Singh, R. B., Singh, S. K., & Kumar, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105212 · Cited by 43
Vitamin D deficiency might pose a greater risk for ApoEɛ4 non-carrier Alzheimer’s disease patients
Dursun, E., Alaylıoğlu, M., Bılgıç, B., Hanagasi, H. A., Lohmann, E., Atasoy, İ. L., Candaş, E., Araz, Ö. S., Önal, B., Gurvit, H. I., et al. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2647-1 · Cited by 44
Self-citationEpigenetic Biomarkers as Diagnostic Tools for Neurodegenerative Disorders
Martínez-Iglesias, O. A., Naidoo, V., Cacabelos, N., & Cacabelos, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010013 · Cited by 42
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
Chen, J.-J., Wang, T., An, C.-D., Jiang, C., Zhao, J., & Li, S. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0017 · Cited by 42
“Similar to IL-4, the AAV serotype 2/1 hybrid-mediated neuronal expression of the mouse IL-10 gene also rescues cognitive impairment in AD mice.”
BackgroundInfluentialHou, C., Peng, Y., Qin, C., Fan, F., Liu, J., & Long, J. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1460749 · Cited by 43
Corrêa, M. S., de Lima, D. B., Giacobbo, B. L., Vedovelli, K., Argimon, I. I. D. L., & Bromberg, E. (2018) · Stress · doi:10.1080/10253890.2018.1510485 · Cited by 44
“…whereas successful therapeutic interventions can increase BDNF levels in these two compartments (Autry & Monteggia, 2012; Diniz & Teixeira, 2011; Gezen-Ak et al., 2013); the severity of neurological symptoms, such as the degree of cognitive impairment, is correlated to serum BDNF levels…”
BackgroundIdentification of inflammatory and vascular markers associated with mild cognitive impairment
Shen, X., Lu, Y., Tan, C. T. Y., Liu, L.-Y., Yu, J., Feng, L., & Larbi, A. (2019) · Aging · doi:10.18632/aging.101924 · Cited by 40
“Some researchers reported that the proinflammatory marker TNF-α increased in the peripheral blood or CSF of patients suffering from Alzheimer’s disease [20, 21].”
BackgroundResultGenetic Factors Affecting Late-Onset Alzheimer’s Disease Susceptibility
Rezazadeh, M., Khorrami, A., Yeghaneh, T., Talebi, M., Kiani, S. J., Heshmati, Y., & Gharesouran, J. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8376-4 · Cited by 37
“Significant elevated serum concentrations of TNFa have been reported in Alzheimer patients compared to controls (Gezen-Ak et al. 2013).”
BackgroundCarboni, L., Lattanzio, F., Candeletti, S., Porcellini, E., Raschi, E., Licastro, F., & Romualdi, P. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.08.012 · Cited by 41
Ihara, K., Yoshida, H., Jones, P. B., Hashizume, M., Suzuki, Y., Ishijima, H., Kim, H., Suzuki, T., & Hachisu, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.47 · Cited by 39
Rahman, S. O., Singh, R. K., Hussain, S., Akhtar, M., & Najmi, A. K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.040 · Cited by 37
Tsai, C., & Pai, M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113013 · Cited by 37
Adrenomedullin Contributes to Age-Related Memory Loss in Mice and Is Elevated in Aging Human Brains
Larráyoz, I. M., Ferrero, H., Martišová, E., Gil-Bea, F. J., Ramírez, M. J., & Martínez, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00384 · Cited by 33
“Although there are no data on the evolution of brain CFH with age, some studies point to a correlation between lower levels of circulating CFH andmore severe cognitive impairment during the development of AD, both in patients (Gezen-Ak et al., 2013) and in mouse models (Wang et al., 2016).”
BackgroundLiu, Z., Guo, J., Wang, Y., Li, K., Kang, J.-F., Wei, Y., Sun, Q., Xu, Q., Xu, C., Yan, X., et al. (2016) · Scientific Reports · doi:10.1038/srep19021 · Cited by 33
Singh, R. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200128121920 · Cited by 33
“These inflammatory mediators propagate and intensify neuroinflammation by a number of mechanisms [80-83].”
BackgroundCarmo, S. D., Crynen, G. C., Paradis, T., Reed, J. M., Iulita, M. F., Ducatenzeiler, A., Crawford, F., & Cuello, A. C. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0580-9 · Cited by 32
“Decreased HSP90 levels have been reported in serum of patients with mild cognitive impairment (MCI) and AD [69] and in the hippocampus of AD patients [70, 71].”
Al‐Rawaf, H. A., Alghadir, A. H., & Gabr, S. A. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s285689 · Cited by 31
The human factor H protein family – an update
Sándor, N., Schneider, A. E., Matola, A. T., Barbai, V. H., Bencze, D., Hammad, H. H., Papp, A., Kövesdi, D., Uzonyi, B., & Józsi, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1135490 · Cited by 33
Li, B., Gao, Y., Zhang, W., & Xu, J. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24187 · Cited by 30
“…have shown that BDNF was diminished in patients with AD and cognition impairment, while the detailed mechanism of the reduction is still complicated (Forlenza et al., 2010; Fumagalli, Racagni, & Riva, 2006; Gezen-Ak et al., 2013; Peng, Wuu, Mufson, & Fahnestock, 2005; Platenik et al., 2014).”
BackgroundInflammatory and Pro-resolving Mediators in Frontotemporal Dementia and Alzheimer’s Disease
Fraga, V. G., Magalhães, C. A., Loures, C. D. M. G., de Souza, L. C., Guimarães, H. C., Zauli, D. A. G., Carvalho, M. D. G., Ferreira, C. N., Caramelli, P., de Sousa, L. P., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.008 · Cited by 28
Metadata
- Authors
- Gezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., & Yılmazer, S.
- Affiliations
- Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University-Cerrahpaşa (TR)
- Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
- Istanbul University (TR)
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2013-08-20
- Volume
- 37
- Issue
- 1
- Pages
- 185-195
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1612435886
- Cited by
- 188
- References
- 22
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 22 · 2019: 16 · 2018: 20 · 2017: 13 · 2016: 18 · 2015: 14 · 2014: 10
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, mild cognitive impairment
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Enzyme-Linked Immunosorbent Assay, Humans, Middle Aged, Regression Analysis, Tumor Necrosis Factor-alpha, Turkey, Cohort Studies, Biomarkers, Case-Control Studies, Interleukin-10, Complement Factor H, Age of Onset, HSP90 Heat-Shock Proteins, Brain-Derived Neurotrophic Factor, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.